What is CytomX Therapeutics, Inc. (CTMX) stock price today?

CytomX Therapeutics, Inc. (CTMX) is currently trading at $2.57, up 4.05% today.

What is CTMX P/E ratio?

CytomX Therapeutics, Inc.'s P/E ratio is -5.69. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CTMX return on equity (ROE)?

CytomX Therapeutics, Inc.'s return on equity (ROE) is -38.46%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is CytomX Therapeutics, Inc.'s market cap?

CytomX Therapeutics, Inc. has a market capitalization of $559.50M.

NASDAQ · Biotechnology

CytomX Therapeutics, Inc. (CTMX) Stock

$2.57 +4.05% NASDAQ: CTMX Healthcare

Valuation

Metric	Value
Price	$2.57
Market Cap	$559.50M
P/E Ratio	-5.69
P/B Ratio	1.86
P/S Ratio	30.45
EPS (TTM)	$0.00
52-Week High	$8.21
52-Week Low	$2.46
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-38.46%
ROA	-20.89%
ROCE	-25.53%
Gross Margin	-30.26%
Operating Margin	-28.95%
Net Margin	-435.21%
Debt/Equity	0.02
Current Ratio	3.06

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$37.0M	$53.0M	$101.0M	$138.0M	$76.0M
Operating Profit	$-116.0M	$-101.0M	$-6.0M	$25.0M	$-22.0M
Net Profit	$-116.0M	$-99.0M	$-1.0M	$32.0M	$-17.0M
EPS	$-1.26	$-1.48	$-0.01	$0.38	$-0.15
Op Margin	-311.0%	-190.6%	-6.4%	18.1%	-29.4%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$339.0M	$261.0M	$202.0M	$121.0M	$152.0M
Total Liabilities	$340.0M	$347.0M	$249.0M	$121.0M	$53.0M
Cash	$206.0M	$194.0M	$17.0M	$38.0M	$13.0M
Borrowings	$22.0M	$18.0M	$14.0M	$9.0M	$4.0M

Latest News

CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why Zacks · Jul 8, 2026 Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now? Insider Monkey · Jun 19, 2026 How The Narrative Around CytomX Therapeutics (CTMX) Is Evolving With Recent Developments Simply Wall St. · Jun 11, 2026 A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results Simply Wall St. · Jun 5, 2026 REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics Zacks · Jun 4, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-119.0M	$-111.0M	$-56.0M	$-86.0M	$-76.0M
Investing Cash Flow	$21.0M	$97.0M	$-152.0M	$99.0M	$-60.0M
Financing Cash Flow	$3.0M	$0	$0	$1.0M	$0
Net Cash Flow	$14.0M	$-12.0M	$-176.0M	$21.0M	$-25.0M
Free Cash Flow	$-121.0M	$-113.0M	$-57.0M	$-87.0M	$-76.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.04
EV / EBITDA	-6.98
FCF Yield	-14.80%
Quick Ratio	9.36
Interest Coverage	0.00
Return 1Y	37.04%
Return 3Y	90.29%
Return 5Y	-37.76%

Ownership

Insiders Held0.53%

Institutions Held96.42%

Institutions Float Held96.93%

Institutional Holder	Shares	Report Date
FMR, LLC	31,955,637	2026-03-31
Kynam Capital Management, LP	15,013,093	2026-03-31
Bank of America Corporation	10,202,785	2026-03-31
Perceptive Advisors Llc	10,098,824	2026-03-31
Venrock Adviser, LLC	9,982,124	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$336.64	-1.11%	38.93	$4.94T	0.32%
MSFTMicrosoft Corporation	$535.07	+2.38%	28.68	$3.97T	0.76%
GOOGLAlphabet Inc.	$351.66	+0.97%	16.94	$4.26T	0.26%
AMZNAmazon.com, Inc.	$262.43	+3.29%	19.82	$2.82T	0.00%
METAMeta Platforms, Inc.	$718.67	-0.31%	27.93	$1.83T	0.28%

About CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. is led by CEO Sean A. McCarthy, employs 119 people, headquartered in US, publicly traded since 2015.

CytomX Therapeutics, Inc. (CTMX) stock trades at $2.57 with a market capitalization of $559.50M. The stock is valued at a price-to-earnings (P/E) ratio of -5.69, price-to-book of 1.86, price-to-sales of 30.45. Over the past 52 weeks the stock has ranged between $2.46 and $8.21, and currently trades 68.7% below its 52-week high.

On profitability, CytomX Therapeutics, Inc. generates a return on equity (ROE) of -38.46%, return on capital employed of -25.53%, an operating margin of -28.95%, a net profit margin of -435.21%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides